NFL Biosciences lists on Euronext Growth Paris

Ignacio Faus, Chief Executive Officer, and Bruno Lafont, co-Founder and Chief Operations Officer of NFL Biosciences, open the trading day in Paris.

NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents.
The company currently has one product in the clinical development phase (NFL-101).